LOS ANGELES--(BUSINESS WIRE)--
CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, announced that President and CEO Steven A. Kriegsman will present at the 2nd Annual Marcum MicroCap Conference on Thursday, May 30, 2013, at 10:00 a.m. Eastern time (7:00 a.m. Pacific time). The conference is being held at the Grand Hyatt hotel in New York City.
A webcast of the presentation will be available on the Company’s website at http://cytrx.com/investors/presentations.
The Marcum MicroCap Conference will allow institutional investors, sell-side analysts and investment bankers the opportunity to consider the investment prospects being showcased by the next generation of up-and-coming microcap companies in seven industries, including Life Sciences. The conference is expected to draw more than 1,000 attendees. Marcum LLC is one of the largest independent public accounting and advisory services firms in the nation. Marcum is a member of the Marcum Group, an organization providing a comprehensive range of professional services spanning accounting and advisory, technology solutions, wealth management, and executive and professional recruiting.
About CytRx Corporation
The CytRx oncology pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, and has initiated a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors. The Company is initiating an international Phase 3 pivotal trial under a special protocol assessment (SPA) with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. CytRx is expanding its pipeline of oncology candidates based on a novel linker platform technology that can be utilized with multiple chemotherapeutic agents and could allow for greater concentration of drug at tumor sites. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib. The Company completed its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib, and is evaluating further development of tamibarotene. For more information about CytRx Corporation, visit www.cytrx.com.
- Health Care Industry
- Pharmaceuticals & Drug Trials